Profile Response Detail

Molecular Profile Unknown unknown
Therapy Docetaxel + Nintedanib
Indication/Tumor Type lung adenocarcinoma
Response Type not applicable
Create By cstatz
Update By cstatz

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung adenocarcinoma not applicable Docetaxel + Nintedanib Phase III Actionable In a Phase III trial, the combination of Ofev (nintedanib) and Taxotere (docetaxel) resulted in an improved overall survival in lung adenocarcinoma patients, particularly those patients with shorter time to progression after first line chemotherapy, which included measures that were time from start or time from end of first line chemotherapy (PMID: 28702806). 28702806
PubMed Id Reference Title Details
(28702806) Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. Full reference...